Dantrolene rescues aberrant N-terminus intersubunit interactions inmutant pro-arrhythmic cardiac ryanodine receptors

Cardiovascular Research

Volumn 105, Issue 1, 2015, Pages 118-128

  Seidel, Monika ^a   Thomas, N Lowri ^a   Williams, Alan J ^a   Lai, F Anthony ^a   Zissimopoulos, Spyros ^a  

^a CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

Arrhythmias; Dantrolene; Excitation contraction coupling; Oligomerization; Ryanodine receptor

Indexed keywords

CALCIUM ION; DANTROLENE; RYANODINE RECEPTOR 2; ANTIARRHYTHMIC AGENT; MUTANT PROTEIN; RYANODINE RECEPTOR;

AMINO TERMINAL SEQUENCE; ARTICLE; CONTROLLED STUDY; CROSS LINKING; HEART ARRHYTHMIA; IMMUNOPRECIPITATION; MISSENSE MUTATION; OLIGOMERIZATION; PRIORITY JOURNAL; SUCROSE DENSITY GRADIENT CENTRIFUGATION; AMINO ACID SUBSTITUTION; ARRHYTHMIAS, CARDIAC; ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA; BIOLOGICAL MODEL; CALCIUM SIGNALING; CHEMISTRY; DRUG EFFECTS; GENETICS; HEART FAILURE; HEART MUSCLE; HEK293 CELL LINE; HUMAN; METABOLISM; PROTEIN DOMAIN; PROTEIN MULTIMERIZATION; PROTEIN STABILITY; SITE DIRECTED MUTAGENESIS; TACHYCARDIA, VENTRICULAR;

AMINO ACID SUBSTITUTION; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIAS, CARDIAC; ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA; CALCIUM SIGNALING; DANTROLENE; HEART FAILURE; HEK293 CELLS; HUMANS; MODELS, CARDIOVASCULAR; MUTAGENESIS, SITE-DIRECTED; MUTANT PROTEINS; MYOCARDIUM; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEIN MULTIMERIZATION; PROTEIN STABILITY; RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL; TACHYCARDIA, VENTRICULAR;

EID: 84929081932     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvu240     Document Type: Article

References (50)

1. Belevych AE, Radwanski PB, Carnes CA, Gyorke S. 'Ryanopathy': causes and manifestations of RyR2 dysfunction in heart failure. Cardiovasc Res 2013;98:240-247.
2. Blayney LM, Lai FA. Ryanodine receptor-mediated arrhythmias and sudden cardiac death. Pharmacol Ther 2009;123:151-177.
3. Marks AR. Calcium cycling proteins and heart failure: mechanisms and therapeutics. J Clin Invest 2013;123:46-52.
4. Priori S, Chen S. Inherited dysfunction of sarcoplasmic reticulum Ca2+ handling and arrhythmogenesis. Circ Res 2011;108:871-883.
5. Priori S, Napolitano C, Tiso N, Memmi M, Vignati G, Bloise R, Sorrentino V, Danieli G. Mutations in the cardiac ryanodine receptor gene (hRyR2) underlie catecholaminergic polymorphic ventricular tachycardia. Circulation 2001;103:196-200.
6. Tiso N, Stephan D, Nava A, Bagattin A, Devaney J, Stanchi F, Larderet G, Brahmbhatt B, Brown K, Bauce B, Muragio M, Basso C, Thiene G, Danieli G, Rampazzo A. Identification of mutations in the cardiac ryanodine receptor gene in families affected with arrhythmogenic right ventricular cardiomyopathy type 2 (ARVD2). Hum Mol Genet 2001;10: 189-194.
7. d'Amati G, Bagattin A, Bauce B, Rampazzo A, Autore C, Basso C, King K, Romeo MD, Gallo P, Thiene G, Danieli GA, Nava A. Juvenile sudden death in a family with polymorphic ventricular arrhythmias caused by a novel RyR2 gene mutation: evidence of specific morphological substrates. Hum Pathol 2005;36:761-767.
8. Tester DJ, Kopplin LJ, Will ML, Ackerman MJ. Spectrum and prevalence of cardiac ryanodine receptor (RyR2) mutations in a cohort of unrelated patients referred explicitly for long QT syndrome genetic testing. Heart Rhythm 2005;2:1099-1105.
9. George C, Higgs G, Lai F. Ryanodine receptor mutations associated with stress-induced ventricular tachycardia mediate increased calcium release in stimulated cardiomyocytes. Circ Res 2003;93:531-540.
10. Jiang D, Wang R, Xiao B, Kong H, Hunt D, Choi P, Zhang L, Chen S. Enhanced store overload-induced Ca2+ release and channel sensitivity to luminal Ca2+ activation are common defects of RyR2 mutations linked to ventricular tachycardia and sudden death. Circ Res 2005;97:1173-1181.
11. Jiang D, Xiao B, Zhang L, ChenS. Enhanced basal activity of a cardiacCa2+release channel (ryanodine receptor) mutant associated with ventricular tachycardia and sudden death. Circ Res 2002;91:218-225.
12. Lehnart S, Wehrens X, Laitinen P, Reiken S, Deng S, Cheng Z, Landry D, Kontula K, Swan H, Marks A. Sudden death in familial ventricular tachycardia associated with calcium release channel (ryanodine receptor) leak. Circulation 2004;109:3208-3214.
13. Thomas L, George C, Lai F. Functional heterogeneity of ryanodine receptor mutations associated with sudden cardiac death. Cardiovasc Res 2004;64:52-60.
14. Uchinoumi H, Yano M, Suetomi T, Ono M, Xu X, Tateishi H, Oda T, Okuda S, Doi M, Kobayashi S, YamamotoT, IkedaY, OhkusaT, Ikemoto N, Matsuzaki M. Catecholaminergic polymorphic ventricular tachycardia is caused by mutation-linked defective conformational regulation of the ryanodine receptor. Circ Res 2010;106:1413-1424.
15. Wehrens X, Lenhart S, Huang F, Vest J, Reiken S, Mohler P, Sun J, Guatimosim S, Song L-S, Rosemblit N, D'Armiento J, Napolitano C, Memmi M, Priori S, Lederer W, Marks A. FKBP12. 6 deficiency and defective calcium release channel (ryanodine receptor) function linked to exercise-induced sudden cardiac death. Cell 2003;113:829-840.
16. Jiang D, ChenW, Wang R, Zhang L, Chen S. Loss of luminal Ca2+ activation in the cardiac ryanodine receptor is associated with ventricular fibrillation and sudden death. Proc Natl Acad Sci USA 2007;104:18309-18314.
17. Avila G, O'Connell K, Dirksen R. The pore region of the skeletal muscle ryanodine receptor is a primary locus for excitation-contraction uncoupling in central core disease. J Gen Physiol 2003;121:277-286.
18. DuG, KhannaV, GuoX, MacLennan D. Central core disease mutationsR4892W, I4897T and G4898E in the ryanodine receptor isoform 1 reduce the Ca2+ sensitivity and amplitude of Ca2+-dependent Ca2+ release. Biochem J 2004;382:557-564.
19. Jiang D, Xiao B, Yang D, Wang R, Choi P, Zhang L, Cheng H, Chen S. RyR2 mutations linked to ventricular tachycardia and sudden death reduce the threshold for store-overload-induced Ca2+ release (SOICR). Proc Natl Acad Sci USA 2004;101: 13062-13067.
20. George C, Jundi H, Walters N, Thomas N, West R, Lai F. Arrhythmogenic mutationlinked defects in ryanodine receptor autoregulation reveal a novel mechanism of Ca2+ release channel dysfunction. Circ Res 2006;98:88-97.
21. Bhat M, Zhao J, Takeshima H, Ma J. Functional calcium release channel formed by the carboxyl-terminal portion of ryanodine receptor. Biophys J 1997;73:1329-1336.
22. Bhat M, Zhao J, ZangW, Balke C, Takeshima H, WierW, MaJ. Caffeine-induced release of intracellular Ca2+ from Chinese hamster ovary cells expressing skeletal muscle ryanodine receptor: effects on full-length and carboxyl-terminal portion of Ca2+ release channels. J Gen Physiol 1997;110:749-762.
23. Gao L, Tripathy A, Lu X, Meissner G. Evidence for a role of C-terminal amino acid residues in skeletal muscle Ca2+ release channel (ryanodine receptor) function. FEBS Lett 1997;412:223-226.
24. George C, Jundi H, Thomas N, Scoote M, Walters N, Williams A, Lai F. Ryanodine receptor regulation by intramolecular interaction between cytoplasmic and transmembrane domains. Mol Biol Cell 2004;15:2627-2638.
25. Wang J, Needleman D, Seryshev A, Aghdasi B, Slavik K, Liu S-Q, Pedersen S, Hamilton S. Interaction between ryanodine and neomycin binding sites on Ca2+ release channel from skeletal muscle sarcoplasmic reticulum. J Biol Chem 1996;271:8387-8393.
26. Zissimopoulos S, Lai F. Ryanodine receptor structure, function and pathophysiology. In: Krebs J, Michalak M, eds. Calcium: A Matter of Life or Death. Vol. 41. Amsterdam, The Netherlands: Elsevier; 2007. p. 287-342.
27. Zissimopoulos S, Marsh J, Stannard L, Seidel M, Lai FA. Amino-terminus oligomerisation is conserved in intracellular calcium release channels. Biochem J 2014;459:265-273.
28. Zissimopoulos S, Viero C, Seidel M, Cumbes B, White J, Cheung I, Stewart R, Jeyakumar LH, Fleischer S, Mukherjee S, Thomas NL, Williams AJ, Lai FA. N-terminus oligomerization regulates the function of cardiac ryanodine receptors. J Cell Sci 2013; 126(Pt 21):5042-5051.
29. Krause T, Gerbershagen MU, Fiege M, Weisshorn R, Wappler F. Dantrolene-a review of its pharmacology, therapeutic use and new developments. Anaesthesia 2004;59: 364-373.
30. Zhao F, Li P, Chen S, Louis C, Fruen B. Dantrolene inhibition of ryanodine receptor Ca2+ release channels. Molecular mechanism and isoform selectivity. J Biol Chem 2001;276: 13810-13816.
31. Jung CB, Moretti A, Mederos y Schnitzler M, Iop L, Storch U, Bellin M, Dorn T, Ruppenthal S, Pfeiffer S, Goedel A, Dirschinger RJ, Seyfarth M, Lam JT, Sinnecker D, Gudermann T, Lipp P, Laugwitz KL. Dantrolene rescues arrhythmogenic RYR2 defect in a patient-specific stem cell model of catecholaminergic polymorphic ventricular tachycardia. EMBO Mol Med 2012;4:180-191.
32. Kobayashi S, Yano M, Suetomi T, Ono M, Tateishi H, Mochizuki M, Xu X, Uchinoumi H, Okuda S, Yamamoto T, Koseki N, Kyushiki H, Ikemoto N, Matsuzaki M. Dantrolene, a therapeutic agent for malignant hyperthermia, markedly improves the function of failing cardiomyocytes by stabilizing interdomain interactions within the ryanodine receptor. J Am Coll Cardiol 2009;53:1993-2005.
33. Kobayashi S, Yano M, Uchinoumi H, Suetomi T, Susa T, Ono M, Xu X, Tateishi H, Oda T, Okuda S, Doi M, Yamamoto T, Matsuzaki M. Dantrolene, a therapeutic agent for malignant hyperthermia, inhibits catecholaminergic polymorphic ventricular tachycardia in a RyR2(R2474S/+) knock-in mouse model. Circ J 2010;74:2579-2584.
34. Maxwell JT, Domeier TL, Blatter LA. Dantrolene prevents arrhythmogenic Ca2+ release in heart failure. Am J Physiol Heart Circ Physiol 2012;302:H953-H963.
35. Paul-Pletzer K, Yamamoto T, Bhat M, Ma J, Ikemoto N, Jimenez L, Morimoto H, Williams P, Parness J. Identification of the dantrolene binding sequence of the skeletal muscle ryanodine receptor. J Biol Chem 2002;277:34918-34923.
36. Paul-Pletzer K, Yamamoto T, Ikemoto N, Jimenez L, Morimoto H, Williams P, Ma J, Parness J. Probing a putative dantrolene-binding site on the cardiac ryanodine receptor. Biochem J 2005;387:905-909.
37. Sutko J, Airey J, Welch W, Ruest L. The pharmacology of ryanodine and related compounds. Pharmacol Rev 1997;49:53-98.
38. Kimlicka L, Tung CC, Carlsson AC, Lobo PA, Yuchi Z, Van Petegem F. The cardiac ryanodine receptor N-terminal region contains an anion binding site that is targeted by disease mutations. Structure 2013;21:1440-1449.
39. Kimlicka L, Lau K, Tung CC, Van Petegem F. Disease mutations in the ryanodine receptor N-terminal region couple to a mobile intersubunit interface. Nat Commun 2013;4:1506.
40. Stewart R, Zissimopoulos S, Lai F. Oligomerization of the cardiac ryanodine receptor C-terminal tail. Biochem J 2003;376:795-799.
41. Shan J, XieW, Betzenhauser M, Reiken S, Chen BX, Wronska A, Marks AR. Calcium leak through ryanodine receptors leads to atrial fibrillation in 3 mouse models of catecholaminergic polymorphic ventricular tachycardia. Circ Res 2012;111:708-717.
42. Kobayashi S, Bannister M, Gangopadhyay J, Hamada T, Parness J, Ikemoto N. Dantrolene stabilizes domain interactionswithin the ryanodine receptor. J Biol Chem2005;280:6580-6587.
43. Wang R, Zhong X, Meng X, Koop A, Tian X, Jones PP, Fruen BR, Wagenknecht T, Liu Z, Chen SR. Localization of the dantrolene-binding sequence near the FK506-binding protein-binding site in the three-dimensional structure of the ryanodine receptor. J Biol Chem 2011;286:12202-12212.
44. Pogwizd S, Bers D. Cellular basis of triggered arrhythmias in heart failure. Trends Cardiovasc Med 2004;14:61-66.
45. Bers D, Eisner D, Valdivia H. Sarcoplasmic reticulum Ca2+ and heart failure: roles of diastolic leak and Ca2+ transport. Circ Res 2003;93:487-490.
46. Hasenfuss G, Pieske B. Calcium cycling in congestive heart failure. J Mol Cell Cardiol 2002; 34:951-969.
47. Awad MM, Calkins H, Judge DP. Mechanisms of disease: molecular genetics of arrhythmogenic right ventricular dysplasia/cardiomyopathy. Nat Clin Pract Cardiovasc Med 2008; 5:258-267.
48. Basso C, Corrado D, Marcus FI, Nava A, Thiene G. Arrhythmogenic right ventricular cardiomyopathy. Lancet 2009;373:1289-1300.
49. Saffitz JE. The pathobiology of arrhythmogenic cardiomyopathy. Annu Rev Pathol 2011;6: 299-321.
50. George C, Higgs G, Mackrill J, Lai F. Dysregulated ryanodine receptors mediate cellular toxicity. J Biol Chem 2003;278:28856-28864.